CN109078072A - It is a kind of for preventing the oral preparation of coronary heart disease - Google Patents
It is a kind of for preventing the oral preparation of coronary heart disease Download PDFInfo
- Publication number
- CN109078072A CN109078072A CN201811272739.2A CN201811272739A CN109078072A CN 109078072 A CN109078072 A CN 109078072A CN 201811272739 A CN201811272739 A CN 201811272739A CN 109078072 A CN109078072 A CN 109078072A
- Authority
- CN
- China
- Prior art keywords
- extract
- oral preparation
- heart disease
- preventing
- coronary heart
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 55
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 23
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 23
- 244000192528 Chrysanthemum parthenium Species 0.000 claims abstract description 21
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 claims abstract description 21
- 239000000203 mixture Substances 0.000 claims abstract description 21
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 20
- 235000008384 feverfew Nutrition 0.000 claims abstract description 20
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 17
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 17
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 17
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 17
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 17
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 17
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 17
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 17
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 17
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 17
- 241001165494 Rhodiola Species 0.000 claims abstract description 17
- 239000002904 solvent Substances 0.000 claims abstract description 13
- 238000010521 absorption reaction Methods 0.000 claims abstract description 9
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 239000007901 soft capsule Substances 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 55
- 239000000284 extract Substances 0.000 claims description 42
- 235000019441 ethanol Nutrition 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 238000001035 drying Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- 241001072909 Salvia Species 0.000 claims description 10
- 235000017276 Salvia Nutrition 0.000 claims description 10
- 239000012530 fluid Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 229940083466 soybean lecithin Drugs 0.000 claims description 8
- 235000019640 taste Nutrition 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 235000020717 hawthorn extract Nutrition 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 239000011148 porous material Substances 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 239000011347 resin Substances 0.000 claims description 5
- 229920005989 resin Polymers 0.000 claims description 5
- 229930182490 saponin Natural products 0.000 claims description 5
- 150000007949 saponins Chemical class 0.000 claims description 5
- 235000017709 saponins Nutrition 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- HYXITZLLTYIPOF-UHFFFAOYSA-N Tanshinone II Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)=CO2 HYXITZLLTYIPOF-UHFFFAOYSA-N 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- AZEZEAABTDXEHR-UHFFFAOYSA-M sodium;1,6,6-trimethyl-10,11-dioxo-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-2-sulfonate Chemical compound [Na+].C12=CC=C(C(CCC3)(C)C)C3=C2C(=O)C(=O)C2=C1OC(S([O-])(=O)=O)=C2C AZEZEAABTDXEHR-UHFFFAOYSA-M 0.000 claims description 3
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N tanshinone IIA Natural products C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 claims description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 2
- 210000002969 egg yolk Anatomy 0.000 claims description 2
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 241001092040 Crataegus Species 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims 1
- 230000010148 water-pollination Effects 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 abstract description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 4
- 230000015556 catabolic process Effects 0.000 abstract description 3
- 238000006731 degradation reaction Methods 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 239000003623 enhancer Substances 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000001151 other effect Effects 0.000 abstract description 2
- 230000032895 transmembrane transport Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004089 microcirculation Effects 0.000 abstract 1
- 240000005373 Panax quinquefolius Species 0.000 description 6
- 235000003140 Panax quinquefolius Nutrition 0.000 description 6
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 5
- 235000008434 ginseng Nutrition 0.000 description 5
- 239000004411 aluminium Substances 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- 206010002383 Angina Pectoris Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- MUKYLHIZBOASDM-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid 2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound NC(=N)N(C)CC(O)=O.OCC(O)C(O)C(O)C(O)C(O)=O MUKYLHIZBOASDM-UHFFFAOYSA-N 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010011086 Coronary artery occlusion Diseases 0.000 description 1
- 206010011089 Coronary artery stenosis Diseases 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- 241000934856 Daphne Species 0.000 description 1
- 244000179525 Dracocephalum moldavica Species 0.000 description 1
- 235000010700 Dracocephalum moldavica Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- 235000003332 Ilex aquifolium Nutrition 0.000 description 1
- 241001450949 Ilex pubescens var. glabra Species 0.000 description 1
- 235000002296 Ilex sandwicensis Nutrition 0.000 description 1
- 235000002294 Ilex volkensiana Nutrition 0.000 description 1
- DBLDQZASZZMNSL-QMMMGPOBSA-N L-tyrosinol Natural products OC[C@@H](N)CC1=CC=C(O)C=C1 DBLDQZASZZMNSL-QMMMGPOBSA-N 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 244000152640 Rhipsalis cassutha Species 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241001078983 Tetradium ruticarpum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241001533104 Tribulus terrestris Species 0.000 description 1
- 240000000260 Typha latifolia Species 0.000 description 1
- 244000126014 Valeriana officinalis Species 0.000 description 1
- 235000013832 Valeriana officinalis Nutrition 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000004330 tyrosol Nutrition 0.000 description 1
- 235000016788 valerian Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of for preventing the oral preparation of coronary heart disease, it is to extract and be made powdered medicament composition as Chinese medicine material using Radix Notoginseng, Radix Salviae Miltiorrhizae, root of kirilow rhodiola, dried orange peel, hawthorn and feverfew, using propylene glycol as solvent, phosphatide complexes are absorption enhancers, and the oral preparation being prepared in conjunction with medicament composition.Oral preparation of the invention significantly enhances the transmembrane transport of arasaponin, tanshin polyphenolic acid B and rhodioside, reduce its degradation in gastrointestinal tract, and then promote the oral absorption of medicament, with help gas yin, activating microcirculation and removing stasis medicinal, the positive dredging collateral of temperature, relieve inflammation or internal heat logical internal organs and other effects, long-term use can be enhanced constitution anti-aging, while it is prepared at soft capsule and capsulae enterosolubilis be not required to decoct, it is convenient to take.
Description
Technical field
The present invention relates to technical field of pharmaceuticals, and in particular to a kind of for preventing the oral preparation of coronary heart disease.
Background technique
Coronary heart disease is the abbreviation of coronary atherosclerotic heart disease, and coronary artery supplies heart self-blood, coronal
Serious atherosis or spasm occur for artery, make coronary artery stenosis or occlusion, lead to one kind of myocardial ischemia-anoxemia or infraction
Heart disease.Main clinical manifestation is angina pectoris, arrhythmia cordis caused by myocardial ischemia, anoxic, and myocardium stalk can occur for serious person
Plug makes myocardium large area necrosis, crisis life.
Currently, the effect of clinical treatment coronary heart disease is not highly desirable, therefore prevents coronary heart disease and is increasingly paid attention to by people,
Wherein traditional Chinese medicine has many advantages, such as good effect, Small side effects by more and more concerns, but there is also weeks for traditional Chinese medicine
Phase is long, taste is bitter, decocts the disadvantages of inconvenient.If its bitter taste is covered, and extracts traditional Chinese medicine active constituent and mouth is made
Formulation, convenient for take for a long time and it is convenient to take.
So far from the end of the seventies, traditional Chinese medicine medical treatment, researcher have made research and spy extensively and profoundly to cmm of simple prescription
It begs for, also achieves certain achievement in terms of folk prescription prevents and treats coronary disease and angina pectoris.There are many research of single medicinal material, specifically
It is as follows: Radix Astragali, ginseng, American Ginseng, Radix Codonopsis, Radix Ophiopogonis, wilsonii, Radix Salviae Miltiorrhizae, pueraria lobata, Rhizoma Chuanxiong, Radix Notoginseng, ginkgo, korean daphne root and stem, oil lamp
It is asarum, Moschus, leech, gadfly, rhizoma corydalis, Fructus Liquidambaris, Dracocephalum moldavica, buxenine, Radix Rhodiolae, pheretima, cattail pollen, hawthorn, red
It is Chinese herbaceous peony, motherwort, iron holly bark, Ilex pubescens var. glabra Chang, water body flower, gynostemma pentaphylla, Fructus Forsythiae, bitter butterfly, Hai Tong, platyphyllous valerian root, wintergreen, green
Tea, evodia rutaecarpa, Rhizoma Gastrodiae, puncture vine, Herba Epimedii, mistletoe, herba taxilli etc..
The active constituent of Radix Notoginseng is arasaponin, and the main component Ginsenosides of arasaponin have polyhydroxy base junction
Structure belongs to hydrophilic compounds, therefore the water-soluble very big and fat-soluble difference of arasaponin, in gastrointestinal tract mucous permeability
It is low, in addition the enzymatic hydrolysis and liver first-pass effect of degradation of the gastric juice acidic environment to drug, gastrointestinal tract and bacterial metabolism enzyme, make original shape
The pharmacological activity of drug cannot achieve.
The active constituent of Radix Salviae Miltiorrhizae is mainly tanshinone IIA and tanshin polyphenolic acid B, and wherein tanshin polyphenolic acid B belongs to biopharmacy III and divides
Class system class drug, i.e. good water solubility, biological membrane permeability is poor, and the permeable membrane for being unfavorable for drug absorbs.
The active constituent of root of kirilow rhodiola is mainly rhodioside and tyrosol, wherein rhodioside good water solubility, biomembrane
Permeability is poor, and the permeable membrane for being also unfavorable for drug absorbs.
Relatively stable compound that phosphatide complexes, which are drug and phospholipid molecule, to be formed by charge transfer interaction or
Complex compound.The physicochemical property of its changeable parent drug, improves bioavilability, and preparation method is simple, low in cost, in recent years
Come using gradually increasing, especially achieved in terms of the research of Chinese medicine phosphatide complexes in terms of pharmaceutical preparation it is biggish at
Just.If by the above medicine preparation be phosphatide complexes after, be conducive to the lipophilicity for improving such drug, so as to improve drug
Permeable membrane absorbs.
Summary of the invention
The present invention is using Radix Notoginseng, Radix Salviae Miltiorrhizae, root of kirilow rhodiola, dried orange peel, hawthorn and feverfew as Chinese medicine material, using propylene glycol as solvent,
Phosphatide complexes are absorption enhancers, are disclosed a kind of for preventing the oral preparation of coronary heart disease.
To achieve the above object, the invention provides the following technical scheme: it is a kind of for preventing the oral preparation of coronary heart disease, it
It is the medicament made of the Chinese medicine material of following weight proportion: Radix Notoginseng 7~15, Radix Salviae Miltiorrhizae 4~10, root of kirilow rhodiola 5~15, dried orange peel 8~
15, hawthorn 10~25, feverfew 5~25.
Preferably, wherein the weight proportion of each raw material is: Radix Notoginseng 12, Radix Salviae Miltiorrhizae 8, root of kirilow rhodiola 10, dried orange peel 12, hawthorn 18, white
Chrysanthemum 15.
Preferably, wherein the preparation method of each raw extract is as follows:
Notogineng Extract: by notoginseng drying and crushing, and is extracted by several times with industrial alcohol, simultaneously merging filtrate is filtered, by filtrate
Vacuum distillation adds water and continues distillation to no alcohol taste, be then adjusted to every 1ml medical fluid with water and be equivalent to 1g crude drug to a certain amount of, general
Medical fluid passes through D101Large pore resin absorption column and with 50% ethanol elution, it is filtering, cooling, make filtrate by being covered with a small amount of neutral oxygen
The funnel for changing aluminium, is recovered under reduced pressure ethyl alcohol, and liquid extract is successively carried out to water-bath evaporation, is dried in vacuo and content of the total saponins in radix notoginseng is made
For the Notogineng Extract of 50%~90% (weight).
Salvia root P.E: it by Radix Salviae Miltiorrhizae drying and crushes, is extracted by several times under cryogenic conditions with hydrophilic solvent, extraction process is not
It breaks off a friendship for pressurization decompression, finally filtered extracting solution is successively concentrated, is dried and tanshinone IIA and tanshin polyphenolic acid B is made
Recovery rate is 95% or more Salvia root P.E.
Gadol extract: it is air-dried after root of kirilow rhodiola is cleaned and is crushed to 120 mesh fineness.
Dried orange peel extracts: 50% ethyl alcohol of dried orange peel is extracted, and discards residue, and extracting solution is successively concentrated, is dried and made
?.
Haw thorn extract: drying after hawthorn is cleaned and is crushed to 120 mesh fineness.
Feverfew flower extract: it is air-dried after feverfew is cleaned and is crushed to 120 mesh fineness.
Preferably, the hydrophilic solvent is methanol aqueous solution, ethanol water or aqueous acetone solution；Wherein methanol, second
The mixed volume ratio of alcohol or acetone and water is 1:2~3:1.
Preferably, each raw extract is formed into medicament composition after evenly mixing, by weight ratio for 1: 0.1~
0.8: 1.2~6: 0~9.6 measure medicament composition, phosphatide complexes, propylene glycol and water respectively, and phosphatide complexes, which are dissolved in, to be had
In solvent, propylene glycol and water is added, organic solvent is removed under reduced pressure in mixing, adds medicament composition and is uniformly mixed to get mixed
Solution is closed, wherein organic solvent is selected from ethyl acetate, tetrahydrofuran, n-hexane, hexamethylene, C1~C6One of low-grade alkane alcohol.
Preferably, the phosphatide complexes are selected from soybean lecithin, yolk phospholipid, milk phosphatide or two palmityl phosphatidyl gallbladders
One of alkali or more than one mixtures.
Preferably, auxiliary material can be added in the mixed solution and is prepared into pharmaceutically acceptable soft capsule or capsulae enterosolubilis.
Compared with prior art, the beneficial effects of the present invention are: it is Radix Notoginseng employed in the present invention, Radix Salviae Miltiorrhizae, root of kirilow rhodiola, old
Skin, hawthorn and feverfew totally six doses of Chinese medicine materials obtained in terms of folk prescription treatment coronary disease and angina pectoris in clinic it is certain at
These Chinese medicine materials are extracted and are made powdered medicament composition, with dried orange peel and the taste masks Radix Notoginseng of hawthorn, pellet by achievement
Ginseng, the bitterness of root of kirilow rhodiola and feverfew, and then improve the mouthfeel of oral preparation；Using propylene glycol as solvent, phosphatide complexes are to promote
Absorbent significantly enhances the transmembrane transport of arasaponin, tanshin polyphenolic acid B and rhodioside, reduces it in gastrointestinal tract
Degradation, and then promote the oral absorption of effective component in medicament；Oral preparation of the invention has help gas yin, promoting blood circulationization
The positive dredging collateral of the stasis of blood, temperature, relieve inflammation or internal heat logical internal organs and other effects, and constitution anti-aging can be enhanced in long-term use；It is prepared simultaneously at soft capsule
With capsulae enterosolubilis be not required to decoct, it is convenient to take.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of for preventing the oral preparation of coronary heart disease in the embodiment of the present invention, it is the Chinese medicine matched by following weight
Medicament made of raw material: Radix Notoginseng 7, Radix Salviae Miltiorrhizae 4, root of kirilow rhodiola 5, dried orange peel 8, hawthorn 10, feverfew 5.
Further, wherein the preparation method of each raw extract is as follows:
Notogineng Extract: by notoginseng drying and crushing, and is extracted by several times with industrial alcohol, simultaneously merging filtrate is filtered, by filtrate
Vacuum distillation adds water and continues distillation to no alcohol taste, be then adjusted to every 1ml medical fluid with water and be equivalent to 1g crude drug to a certain amount of, general
Medical fluid passes through D101Large pore resin absorption column and with 50% ethanol elution, it is filtering, cooling, make filtrate by being covered with a small amount of neutral oxygen
The funnel for changing aluminium, is recovered under reduced pressure ethyl alcohol, and liquid extract is successively carried out to water-bath evaporation, is dried in vacuo and content of the total saponins in radix notoginseng is made
For the Notogineng Extract of 50%~90% (weight).
Salvia root P.E: it by Radix Salviae Miltiorrhizae drying and crushes, the ethanol water point for being 1:2 with mixed volume ratio under cryogenic conditions
Secondary extraction, extraction process constantly alternately pressurization decompression, is finally successively concentrated, is dried and is made red for filtered extracting solution
Ginseng ketone IIA and tanshin polyphenolic acid B recovery rate are 95% or more Salvia root P.E.
Gadol extract: it is air-dried after root of kirilow rhodiola is cleaned and is crushed to 120 mesh fineness.
Dried orange peel extracts: 50% ethyl alcohol of dried orange peel is extracted, and discards residue, and extracting solution is successively concentrated, is dried and made
?.
Haw thorn extract: drying after hawthorn is cleaned and is crushed to 120 mesh fineness.
Feverfew flower extract: it is air-dried after feverfew is cleaned and is crushed to 120 mesh fineness.
Further, each raw extract is formed into medicament composition after evenly mixing, is by weight ratio 1: 0.4: 8.4
Medicament composition, soybean lecithin, propylene glycol are measured respectively, soybean lecithin is dissolved in ethyl acetate solvent, propylene glycol is added, and are mixed
It closes, ethyl acetate solvent is removed under reduced pressure, add medicament composition and be uniformly mixed to get mixed solution.
Embodiment 2
A kind of for preventing the oral preparation of coronary heart disease in the embodiment of the present invention, it is the Chinese medicine matched by following weight
Medicament made of raw material: Radix Notoginseng 12, Radix Salviae Miltiorrhizae 8, root of kirilow rhodiola 10, dried orange peel 12, hawthorn 18, feverfew 15.
Further, wherein the preparation method of each raw extract is as follows:
Notogineng Extract: by notoginseng drying and crushing, and is extracted by several times with industrial alcohol, simultaneously merging filtrate is filtered, by filtrate
Vacuum distillation adds water and continues distillation to no alcohol taste, be then adjusted to every 1ml medical fluid with water and be equivalent to 1g crude drug to a certain amount of, general
Medical fluid passes through D101Large pore resin absorption column and with 50% ethanol elution, it is filtering, cooling, make filtrate by being covered with a small amount of neutral oxygen
The funnel for changing aluminium, is recovered under reduced pressure ethyl alcohol, and liquid extract is successively carried out to water-bath evaporation, is dried in vacuo and content of the total saponins in radix notoginseng is made
For the Notogineng Extract of 50%~90% (weight).
Salvia root P.E: it by Radix Salviae Miltiorrhizae drying and crushes, the ethanol water point for being 2:1 with mixed volume ratio under cryogenic conditions
Secondary extraction, extraction process constantly alternately pressurization decompression, is finally successively concentrated, is dried and is made red for filtered extracting solution
Ginseng ketone IIA and tanshin polyphenolic acid B recovery rate are 95% or more Salvia root P.E.
Gadol extract: it is air-dried after root of kirilow rhodiola is cleaned and is crushed to 120 mesh fineness.
Dried orange peel extracts: 50% ethyl alcohol of dried orange peel is extracted, and discards residue, and extracting solution is successively concentrated, is dried and made
?.
Haw thorn extract: drying after hawthorn is cleaned and is crushed to 120 mesh fineness.
Feverfew flower extract: it is air-dried after feverfew is cleaned and is crushed to 120 mesh fineness.
Further, each raw extract is formed into medicament composition after evenly mixing, is by weight ratio 1: 0.4: 8.4
Medicament composition, soybean lecithin, the aqueous solution of propylene glycol that weight ratio is 90% are measured respectively, and soybean lecithin is dissolved in alcohol solvent
In, aqueous solution of propylene glycol is added, alcohol solvent is removed under reduced pressure in mixing, and it is uniformly mixed molten to get mixing to add medicament composition
Liquid.
Embodiment 3
A kind of for preventing the oral preparation of coronary heart disease in the embodiment of the present invention, it is the Chinese medicine matched by following weight
Medicament made of raw material: Radix Notoginseng 15, Radix Salviae Miltiorrhizae 10, root of kirilow rhodiola 15, dried orange peel 15, hawthorn 25, feverfew 25.
Further, wherein the preparation method of each raw extract is as follows:
Notogineng Extract: by notoginseng drying and crushing, and is extracted by several times with industrial alcohol, simultaneously merging filtrate is filtered, by filtrate
Vacuum distillation adds water and continues distillation to no alcohol taste, be then adjusted to every 1ml medical fluid with water and be equivalent to 1g crude drug to a certain amount of, general
Medical fluid passes through D101Large pore resin absorption column and with 50% ethanol elution, it is filtering, cooling, make filtrate by being covered with a small amount of neutral oxygen
The funnel for changing aluminium, is recovered under reduced pressure ethyl alcohol, and liquid extract is successively carried out to water-bath evaporation, is dried in vacuo and content of the total saponins in radix notoginseng is made
For the Notogineng Extract of 50%~90% (weight).
Salvia root P.E: it by Radix Salviae Miltiorrhizae drying and crushes, the ethanol water point for being 3:1 with mixed volume ratio under cryogenic conditions
Secondary extraction, extraction process constantly alternately pressurization decompression, is finally successively concentrated, is dried and is made red for filtered extracting solution
Ginseng ketone IIA and tanshin polyphenolic acid B recovery rate are 95% or more Salvia root P.E.
Gadol extract: it is air-dried after root of kirilow rhodiola is cleaned and is crushed to 120 mesh fineness.
Dried orange peel extracts: 50% ethyl alcohol of dried orange peel is extracted, and discards residue, and extracting solution is successively concentrated, is dried and made
?.
Haw thorn extract: drying after hawthorn is cleaned and is crushed to 120 mesh fineness.
Feverfew flower extract: it is air-dried after feverfew is cleaned and is crushed to 120 mesh fineness.
Further, each raw extract is formed into medicament composition after evenly mixing, is by weight ratio 1: 0.4: 8.4
Medicament composition, soybean lecithin, the aqueous solution of propylene glycol that weight ratio is 80% are measured respectively, and soybean lecithin is dissolved in alcohol solvent
In, propylene glycol is added, alcohol solvent is removed under reduced pressure in mixing, adds medicament composition and is uniformly mixed to get mixed solution.
Embodiment 4
Mixed solution obtained is appropriate in Example 1,2 or 3, directly filling in enteric liquid hard capsule, and enteric is made
Liquid hard capsule.
Embodiment 5
Mixed solution obtained is appropriate in Example 1,2 or 3, and enteric soft capsules are made.
Embodiment 6
Mixed solution obtained is appropriate in Example 1,2 or 3, and enteric-coated microcapsule is made.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (7)
1. a kind of for preventing the oral preparation of coronary heart disease, it is characterised in that it is made of the Chinese medicine material that following weight matches
Medicament: Radix Notoginseng 7~15, Radix Salviae Miltiorrhizae 4~10, root of kirilow rhodiola 5~15, dried orange peel 8~15, hawthorn 10~25, feverfew 5~25.
2. it is according to claim 1 a kind of for preventing the oral preparation of coronary heart disease, wherein the weight proportion of each raw material is:
Radix Notoginseng 12, Radix Salviae Miltiorrhizae 8, root of kirilow rhodiola 10, dried orange peel 12, hawthorn 18, feverfew 15.
3. it is according to claim 1 or 2 a kind of for preventing the oral preparation of coronary heart disease, wherein the system of each raw extract
Standby mode is as follows:
Notogineng Extract: by notoginseng drying and crushing, and is extracted by several times with industrial alcohol, simultaneously merging filtrate is filtered, by filtrate decompression
Distillation adds water and continues distillation to no alcohol taste, be then adjusted to every 1ml medical fluid with water and be equivalent to 1g crude drug, by medical fluid to a certain amount of
Pass through D101Large pore resin absorption column and with 50% ethanol elution, it is filtering, cooling, make filtrate by being covered with a small amount of neutral alumina
Funnel, ethyl alcohol is recovered under reduced pressure, liquid extract is successively carried out water-bath evaporation, be dried in vacuo and be made content of the total saponins in radix notoginseng be
The Notogineng Extract of 50%~90% (weight).
Salvia root P.E: it by Radix Salviae Miltiorrhizae drying and crushes, is extracted by several times under cryogenic conditions with hydrophilic solvent, extraction process is not broken off a friendship
For pressurization decompression, filtered extracting solution is successively finally concentrated, is dried and is made tanshinone IIA and tanshin polyphenolic acid B extracts
Rate is 95% or more Salvia root P.E.
Gadol extract: it is air-dried after root of kirilow rhodiola is cleaned and is crushed to 120 mesh fineness.
Dried orange peel extracts: 50% ethyl alcohol of dried orange peel is extracted, and discards residue, and extracting solution is successively concentrated, is dried and is made.
Haw thorn extract: drying after hawthorn is cleaned and is crushed to 120 mesh fineness.
Feverfew flower extract: it is air-dried after feverfew is cleaned and is crushed to 120 mesh fineness.
4. according to claim 3 a kind of for preventing the oral preparation of coronary heart disease, it is characterised in that: the hydrophily is molten
Agent is methanol aqueous solution, ethanol water or aqueous acetone solution；Wherein the mixed volume ratio of methanol, ethyl alcohol or acetone and water is 1:
2~3:1.
5. according to claim 3 a kind of for preventing the preparation method of the oral preparation of coronary heart disease, it is characterised in that: will
Each raw extract forms medicament composition after evenly mixing, is by weight ratio 1: 0.1~0.8: 1.2~6: 0~9.6
Medicament composition, phosphatide complexes, propylene glycol and water are measured respectively, phosphatide complexes are dissolved in organic solvent, are added the third two
Alcohol and water, mixing, is removed under reduced pressure organic solvent, adds medicament composition and is uniformly mixed to get mixed solution, wherein organic molten
Agent is selected from ethyl acetate, tetrahydrofuran, n-hexane, hexamethylene, C1~C6One of low-grade alkane alcohol.
6. according to claim 5 a kind of for preventing the preparation method of the oral preparation of coronary heart disease, it is characterised in that: institute
It states phosphatide complexes and is selected from one of soybean lecithin, yolk phospholipid, milk phosphatide or dipalmitoylphosphatidylcholine or a kind of
The above mixture.
7. according to claim 5 a kind of for preventing the preparation method of the oral preparation of coronary heart disease, it is characterised in that: institute
Auxiliary material can be added by stating in mixed solution is prepared into pharmaceutically acceptable soft capsule or capsulae enterosolubilis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811272739.2A CN109078072A (en) | 2018-10-30 | 2018-10-30 | It is a kind of for preventing the oral preparation of coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811272739.2A CN109078072A (en) | 2018-10-30 | 2018-10-30 | It is a kind of for preventing the oral preparation of coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109078072A true CN109078072A (en) | 2018-12-25 |
Family
ID=64844240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811272739.2A Pending CN109078072A (en) | 2018-10-30 | 2018-10-30 | It is a kind of for preventing the oral preparation of coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109078072A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180291A (en) * | 2022-07-19 | 2023-12-08 | 北京斯高科技有限公司 | Salidroside or radix Rhodiolae extract for preparing voltage-gated sodium channel agonist |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931236A (en) * | 2005-09-14 | 2007-03-21 | 蔡军 | Medicine composition of red sage and rhodiola root |
| CN103006838A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
-
2018
- 2018-10-30 CN CN201811272739.2A patent/CN109078072A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931236A (en) * | 2005-09-14 | 2007-03-21 | 蔡军 | Medicine composition of red sage and rhodiola root |
| CN103006838A (en) * | 2013-01-05 | 2013-04-03 | 山东沃华医药科技股份有限公司 | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases |
Non-Patent Citations (4)
| Title |
|---|
| 刘仲则等: "《天然食物与人体保健》", 29 February 2000, 人民卫生出版社 * |
| 史丽萍: "《图解食养食疗》", 31 January 2018, 中国医药科技出版社 * |
| 墨客文档资源旗舰店: "田七、山楂、丹参配伍用于多种疾病的防治", 《HTTPS://WENKU.BAIDU.COM/VIEW/6EB6B5FCC281E53A5902FFCC.HTML》 * |
| 梅全喜: "《现代中药药理与临床应用手册》", 31 October 2016, 中国中医药出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117180291A (en) * | 2022-07-19 | 2023-12-08 | 北京斯高科技有限公司 | Salidroside or radix Rhodiolae extract for preparing voltage-gated sodium channel agonist |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102423352B (en) | Preparation method of Chinese medicinal granules for treating cardio-cerebrovascular diseases | |
| CN104666373A (en) | Novel use of Eurycoma longifolia Jack | |
| CN101538296B (en) | Active ingredients of camptosorus sibiricus, and extraction method and use of same | |
| CN102119964B (en) | A kind of prevention and the extract for the treatment of angina pectoris, their Preparation method and use | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN106432385A (en) | Preparation method for high-purity breviscapine extract as well as preparations and application thereof | |
| CN101371882A (en) | Method for preparing Artemisia capillaris decoction formulation | |
| CN101085802B (en) | Method for preparing Notoginsen triterpenes | |
| CN109078072A (en) | It is a kind of for preventing the oral preparation of coronary heart disease | |
| CN100464766C (en) | Medicinal composition for treating acute and chronic congestive heart failure, its preparation and use | |
| CN101549010B (en) | A preparing method and application of malaytea scurfpea fruit total glycosides extract | |
| CN101890063B (en) | Chinese medicament for reducing blood sugar and preparation method thereof | |
| CN101194964A (en) | Coated tablet for treating headache and method for preparing the same | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN101974011B (en) | New compound methyl brevicate with medical activity | |
| CN101310739B (en) | Cassia Tuckahoe composition and preparation method thereof | |
| CN114042054A (en) | Method for preparing Chinese herbal medicine extract microcapsule | |
| CN113413407A (en) | Traditional Chinese medicine composition for promoting blood circulation to remove blood stasis and application thereof | |
| CN1321484A (en) | Medicine for curing coronary heart disease with hypertension and its preparation process | |
| CN1559523A (en) | Naodesheng soft capsule and its preparation method | |
| CN1899393A (en) | Chinese medicine compound preparation for treating pulmonary heart disease and its preparation | |
| CN101974010B (en) | New compound erigeron breviscapus acid with officinal activity | |
| CN101574454B (en) | Restoration traditional Chinese medicine | |
| CN101049338B (en) | Composition of Chinese traditional medicine for treating cardiovascular disease and cerebrovascular disease | |
| CN101554399B (en) | Psoralea corylifolial extract with immunologic enhancement and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181225 |
|
| RJ01 | Rejection of invention patent application after publication |